Comparative efficacy and safety of rimegepant versus placebo in the treatment of acute migraine: A meta-analysis with sub-group analysis in the Asian population.
- Author:
Frances Leah ATIENZA
1
;
Danica LEYCANO
1
;
Joyce Ann MACASAET-SMIT
1
Author Information
- Publication Type:Review Articles (Literature/ Systematic /Meta-analysis)
- Keywords: Cgrp - Calcitonin Gene-related Peptide; Acute Migraine
- MeSH: Human; Calcitonin Gene-related Peptide; Rimegepant Sulfate
- From: Philippine Journal of Neurology 2025;28(1):25-35
- CountryPhilippines
- Language:English
-
Abstract:
BACKGROUND
Acute migraine can be treated with rimegepant, an antagonist of the calcitonin gene-related peptide (CGRP) receptor. With a focus on the Asian population as a subgroup, this metaanalysis attempts to investigate the effectiveness and safety of rimegepant for individuals suffering from severe migraines.
METHODSPubMed, MEDLINE database and Cochrane Library were used to identify valid randomized controlled trials for this study. The primary endpoint investigated was freedom from pain and freedom from the most bothersome symptom 2 hours post dose. RevMan 5.4.1 software was used to perform a meta-analysis on each outcome measure.
RESULTSA total of five randomized controlled trials were incorporated, with two of them being conducted on Asian populations and published between 2014 and 2024. There were 2,516 cases in the rimegepant group and 2,668 cases in the placebo group out of the total 5,184 patients that were included. Rimegepant was found to significantly reduce the primary endpoints in acute migraine patients (RR 1.58, 95% CI 1.42-1.75, P-value 0.0001; RR 1.34, 95% CI 1.08-1.66, Pvalue 0.0001), and in the acute migraine Asian patients (RR 1.79, 95% CI 1.47-2.19, P-valueCONCLUSION
The use of rimegepant is effective and safe for acute migraine patients, including the Asian subgroup.
